Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
5.89 USD | -1.83% | +5.94% | -41.86% |
Financials (USD)
Sales 2024 * | 28.8M | Sales 2025 * | 24.83M | Capitalization | 484M |
---|---|---|---|---|---|
Net income 2024 * | -223M | Net income 2025 * | -250M | EV / Sales 2024 * | 8.77 x |
Net cash position 2024 * | 232M | Net cash position 2025 * | 95.12M | EV / Sales 2025 * | 15.7 x |
P/E ratio 2024 * |
-2.24
x | P/E ratio 2025 * |
-2.3
x | Employees | 265 |
Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 99.62% |
Latest transcript on Editas Medicine, Inc.
1 day | -1.83% | ||
1 week | +5.94% | ||
Current month | +13.05% | ||
1 month | +0.68% | ||
3 months | -27.73% | ||
6 months | -32.92% | ||
Current year | -41.86% |
Managers | Title | Age | Since |
---|---|---|---|
Gilmore O’Neill
CEO | Chief Executive Officer | 59 | 22-05-31 |
Erick Lucera
DFI | Director of Finance/CFO | 57 | 23-05-16 |
Linda Burkly
CTO | Chief Tech/Sci/R&D Officer | - | 23-07-23 |
Members of the board | Title | Age | Since |
---|---|---|---|
Emma Reeve
CHM | Chairman | 63 | 21-09-02 |
David Scadden
BRD | Director/Board Member | 71 | 19-02-05 |
Akshay Vaishnaw
BRD | Director/Board Member | 61 | 16-07-27 |
Name | Weight | AuM | 1st Jan change | Investor Rating |
---|---|---|---|---|
4.83% | 2 M€ | -25.75% | ||
0.13% | 2 M€ | -.--% | ||
0.09% | 0 M€ | 0.00% | - | |
0.06% | 0 M€ | 0.00% | - |
Date | Price | Change | Volume |
---|---|---|---|
24-05-16 | 5.89 | -1.83% | 1,650,447 |
24-05-15 | 6 | +5.63% | 2,445,652 |
24-05-14 | 5.68 | -0.53% | 1,625,855 |
24-05-13 | 5.71 | +7.33% | 1,925,180 |
24-05-10 | 5.32 | -4.32% | 1,637,650 |
Delayed Quote Nasdaq, May 16, 2024 at 04:00 pm EDT
More quotesEPS Revisions
1st Jan change | Capi. | |
---|---|---|
-41.86% | 484M | |
+33.37% | 50.85B | |
+1.55% | 42.82B | |
+48.49% | 42.03B | |
-4.22% | 29.55B | |
+11.57% | 26.11B | |
-21.00% | 19.13B | |
+7.36% | 13.05B | |
+28.30% | 12.16B | |
+23.80% | 12.08B |
- Stock Market
- Equities
- EDIT Stock